Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

43.38 -0.23 (-0.53%)
Streaming Delayed Price Updated: 1:54 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy?
All of the top 20 drugmakers have a subscription with this software business. 
Via The Motley Fool
Topics Artificial Intelligence
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
From Bristol Myers Squibb
Via Business Wire
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal
Via Stocktwits
Price Over Earnings Overview: Bristol-Myers Squibb
 
Via Benzinga
Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portfolio. 
Via Benzinga
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
From Bristol Myers Squibb
Via Business Wire
3 Value Stocks with Warning Signs
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a High Dividend Yield and Strong Profitability
Bristol Myers Squibb (BMY) offers a high 5.42% dividend yield with strong profitability and a decade of consistent payouts, making it a top stock for income investors. 
Via Chartmill
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Presents a Strong Value Investment Case
Bristol-Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a solid 5.4% dividend yield, presenting a compelling case for value investors. 
Via Chartmill
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount. 
Via Benzinga
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday. 
Via Chartmill
Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a... 
Via MarketMinute
Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
In today's session, there are S&P500 stocks with remarkable trading volume.
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session. 
Via Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 5.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its... 
Via StockStory
Topics Artificial Intelligence
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
 
Via Benzinga
Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
From Bristol Myers Squibb
Via Business Wire
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
Trump's Plan To Lower U.S. Drug Prices Faces Big Test
But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts. 
Via Investor's Business Daily
Topics Government
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program
The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries. 
Via Stocktwits
Topics Government
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly... 
Via Benzinga
Topics Government World Trade
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.